Neuromuscular Blockers - Pharmacology

SECTION 1

Historical Context & Motivation

The clinical use of neuromuscular blockers has its origins in the indigenous peoples of South America, who for centuries applied plant-derived poisons to blowgun darts to paralyze prey during hunts. The active principle in these preparations — curare — fascinated European explorers and scientists from the sixteenth century onward, setting the stage for a pharmacological revolution in surgical practice. Before the introduction of neuromuscular blocking agents, surgeons relied on deep general anesthesia alone to achieve the skeletal muscle relaxation required for abdominal and thoracic procedures, a practice associated with significant cardiopulmonary depression and mortality. The quest to separate muscle relaxation from anesthetic depth drove researchers to purify curare alkaloids, characterize their mechanism of action at the nicotinic acetylcholine receptor (nAChR), and ultimately develop an entire class of agents that remain indispensable in modern anesthesiology, critical care, and emergency medicine.

1516 • First European Accounts of Curare

Spanish explorer Pedro Mártir de Anglería documented the use of poisoned arrows by indigenous South American peoples, introducing curare to the Western world.

1856 • Claude Bernard's Landmark Experiment

The French physiologist Claude Bernard demonstrated that curare acts at the junction between nerve and muscle rather than on the nerve or muscle alone, establishing the concept of the neuromuscular junction as a discrete pharmacological target.

1942 • Clinical Introduction of Tubocurarine

Harold Griffith and Enid Johnson used purified tubocurarine (Intocostrin) during a surgical appendectomy in Montreal, marking the first deliberate clinical use of a neuromuscular blocker to facilitate general anesthesia.

1951 • Succinylcholine Enters Practice

Succinylcholine, a depolarizing neuromuscular blocker with rapid onset and ultra-short duration, was introduced clinically, transforming rapid-sequence intubation and emergency airway management.

2015 • Sugammadex Revolutionizes Reversal

The FDA approved sugammadex, a modified γ-cyclodextrin capable of encapsulating steroidal neuromuscular blockers like rocuronium, offering a novel mechanism for rapid and complete reversal of neuromuscular blockade.

From Claude Bernard's demonstration that curare targets the nerve–muscle interface to the development of modern agents with predictable pharmacokinetics and reliable reversal, the central question driving this field has remained constant: How can we selectively block nicotinic receptor–mediated neurotransmission at skeletal muscle while minimizing autonomic and systemic side effects? Understanding the pharmacology of these agents is essential for any healthcare professional involved in perioperative care, critical care sedation, or emergency airway management.

SECTION 2

Core Principles & Definitions

Neuromuscular blockers act at the neuromuscular junction (NMJ), the specialized synapse where a motor neuron's axon terminal meets the skeletal muscle fiber at the motor end plate. Under normal physiology, an action potential arriving at the nerve terminal triggers calcium-dependent exocytosis of acetylcholine (ACh) into the synaptic cleft. ACh then binds to nicotinic acetylcholine receptors (N_M subtype) on the postjunctional membrane, opening ligand-gated sodium channels and generating an end-plate potential (EPP) that, when exceeding threshold, initiates a muscle action potential and subsequent contraction. Neuromuscular blockers interrupt this cascade by interfering with ACh's ability to activate these receptors, and they do so through two fundamentally different mechanisms.

Depolarizing Blockers

These agents, exemplified by succinylcholine, mimic ACh and initially activate the nAChR, producing transient depolarization (fasciculations) followed by a sustained block — a Phase I (desensitization) block — because the receptor cannot reprime while the agonist persists.

Non-Depolarizing Blockers

These agents competitively bind the α-subunits of the nAChR without activating the ion channel, thereby preventing ACh from triggering an EPP. Examples include tubocurarine, rocuronium, vecuronium, cisatracurium, and pancuronium.

The Safety Margin of Neuromuscular Transmission

Under normal conditions, far more ACh is released than is needed to reach threshold — a large margin of safety. Approximately 70–80% of receptors must be occupied by a non-depolarizing agent before clinically detectable weakness occurs, and over 90% must be blocked for complete paralysis.

Reversal of Blockade

Non-depolarizing block can be reversed by anticholinesterases (e.g., neostigmine) that increase synaptic ACh concentration, or by sugammadex, which directly encapsulates steroidal agents. Succinylcholine is not reversed pharmacologically — it is rapidly hydrolyzed by plasma cholinesterase (butyrylcholinesterase).

✦

KEY TAKEAWAY

Think of the nicotinic receptor as a locked gate that only opens when the correct key — ACh — is inserted. A depolarizing blocker is like a duplicate key that opens the gate once but then gets stuck in the lock, jamming it open so it can never reset. A non-depolarizing blocker is a blank key that fits snugly into the keyhole but cannot turn the tumbler, simply blocking the real key from entering. Both strategies prevent the gate from cycling normally, but they do so through entirely distinct mechanisms, which explains their different clinical profiles and side effects.

SECTION 3

Visual Explanation — The Neuromuscular Junction

Left panel: normal neuromuscular transmission, in which ACh (cyan circles) binds nAChRs (green channels), producing an EPP and contraction. Right panel: non-depolarizing blockade, in which blocker molecules (orange, with red arrows) occupy the receptor binding sites, preventing ACh from opening the channel and resulting in paralysis.

The diagram above illustrates the critical distinction between physiological neuromuscular transmission and pharmacological blockade. In the left panel, ACh molecules released from the motor nerve terminal cross the synaptic cleft and bind the two α-subunits on each pentameric nAChR complex (α₂βδε), triggering a conformational change that opens the central cation channel. Sodium influx depolarizes the motor end plate, generating an EPP that exceeds threshold and propagates as a full action potential along the muscle fiber. In the right panel, a non-depolarizing agent such as rocuronium occupies the α-subunit binding sites without inducing the conformational change required to open the channel. Because both α-subunits must be occupied by ACh for channel opening, blockade of even one site is sufficient to prevent transmission. The competitive nature of this interaction means that increasing synaptic ACh concentration — for example, by administering an anticholinesterase — can displace the blocker and restore neuromuscular function.

SECTION 4

Mechanisms of Action — Depolarizing vs. Non-Depolarizing

Phase I and Phase II Block (Depolarizing Agents)

Succinylcholine, the only depolarizing neuromuscular blocker in clinical use, is structurally composed of two ACh molecules linked end-to-end. Upon intravenous administration, it rapidly binds and activates nAChRs across all motor end plates, producing a brief period of uncoordinated muscle contraction visible as fasciculations. Unlike ACh, succinylcholine is not immediately hydrolyzed by acetylcholinesterase at the NMJ; instead, it persists at the receptor, maintaining the end plate in a depolarized state. The voltage-gated sodium channels in the perijunctional zone become inactivated, and the muscle fiber cannot repolarize and generate a new action potential. This is Phase I block, characterized on a peripheral nerve stimulator by a uniformly decreased train-of-four (TOF) ratio without fade.

With prolonged or repeated succinylcholine exposure, the character of the block may change to Phase II block (also called desensitization block), which clinically resembles a non-depolarizing block — exhibiting TOF fade and post-tetanic potentiation. The mechanism of Phase II block likely involves conformational changes in the receptor that render it unresponsive to agonists even after repolarization, a phenomenon known as receptor desensitization. Clinically, Phase II block is unpredictable and difficult to reverse, which is one reason succinylcholine is used primarily for brief procedures such as rapid-sequence intubation.

Competitive Antagonism (Non-Depolarizing Agents)

Non-depolarizing agents are bulky quaternary ammonium compounds that bind competitively to one or both α-subunits of the nAChR. Because they do not possess intrinsic efficacy, they stabilize the receptor in its closed conformation. The degree of blockade depends on the relative concentrations of ACh and the blocking agent at the receptor, following the principles of competitive pharmacodynamics. The dose–response relationship can be described using the Hill equation adapted for receptor occupancy.

RECEPTOR OCCUPANCY (HILL EQUATION)

Fractional Block = [NMB]ⁿ / (EC₅₀ⁿ + [NMB]ⁿ)

Where [NMB] is the plasma concentration of the neuromuscular blocker, EC₅₀ is the concentration producing 50% block, and n is the Hill coefficient (typically 3–5 for NMB agents, reflecting the steep dose–response curve).

The steep Hill coefficient for neuromuscular blockers has important clinical implications: small increases in plasma concentration near the EC₅₀ produce disproportionately large increases in the degree of blockade, whereas the large margin of safety (70–80% receptor occupancy required before any clinical weakness is observed) means that substantial drug must accumulate before paralysis becomes evident. This pharmacodynamic profile underlies the concept of "all-or-none" clinical response seen with neuromuscular blockers in practice.

SUCCINYLCHOLINE METABOLISM

Succinylcholine → Succinylmonocholine + Choline (via plasma cholinesterase)

Succinylcholine is rapidly hydrolyzed by butyrylcholinesterase (plasma cholinesterase, also called pseudocholinesterase) in the plasma, yielding succinylmonocholine (a weak, non-depolarizing metabolite) and choline. This rapid hydrolysis accounts for its ultra-short duration of action (5–10 minutes).

SECTION 5

Classification of Non-Depolarizing Agents

Non-depolarizing neuromuscular blockers are classified by their chemical structure into two major families: aminosteroidal compounds and benzylisoquinolinium compounds. This structural distinction has direct pharmacological consequences: aminosteroidal agents tend to be metabolized hepatically and may have vagolytic effects, while benzylisoquinolinium agents undergo Hofmann elimination and ester hydrolysis and are more likely to cause histamine release. Both families are further subclassified by duration of action into short-, intermediate-, and long-acting agents. The table below summarizes the key pharmacokinetic and clinical properties of the most commonly encountered agents.

Agent	Class	Onset (min)	Duration (min)	Metabolism / Elimination	Notable Properties
Succinylcholine	Depolarizing	0.5–1	5–10	Plasma cholinesterase hydrolysis	Fastest onset; fasciculations; hyperkalemia risk; malignant hyperthermia trigger
Rocuronium	Aminosteroidal	1–2	30–60	Hepatic uptake; biliary & renal excretion	Fastest onset among non-depolarizers; reversible by sugammadex
Vecuronium	Aminosteroidal	2–3	25–40	Hepatic metabolism; renal excretion	Minimal cardiovascular effects; reversible by sugammadex
Pancuronium	Aminosteroidal	3–5	60–120	Renal excretion (70%); hepatic (15–20%)	Long-acting; vagolytic → tachycardia; used in ICU and cardiac surgery
Cisatracurium	Benzylisoquinolinium	3–5	30–45	Hofmann elimination (organ-independent)	Ideal in hepatic/renal failure; minimal histamine release; laudanosine metabolite
Atracurium	Benzylisoquinolinium	2–3	25–35	Hofmann elimination + ester hydrolysis	Histamine release at high doses; organ-independent metabolism

Pharmacokinetic and clinical properties of commonly used neuromuscular blockers

Classification tree of neuromuscular blockers showing the depolarizing agent (succinylcholine, pink), aminosteroidal non-depolarizing agents (violet), and benzylisoquinolinium non-depolarizing agents (cyan), along with their respective reversal strategies.

💡

Clinical Pearl

Cisatracurium undergoes Hofmann elimination — a spontaneous, non-enzymatic chemical degradation that occurs at physiological pH and temperature. This makes it the agent of choice in patients with significant hepatic or renal impairment, as its clearance is completely independent of organ function.

SECTION 6

Worked Example — Clinical Scenario

A 70 kg patient is scheduled for an emergent laparotomy. The anesthesiologist plans to perform rapid-sequence intubation (RSI). Succinylcholine is relatively contraindicated due to the patient's history of a recent burn injury (risk of life-threatening hyperkalemia). The team decides to use rocuronium at an RSI dose of 1.2 mg/kg for intubation, with sugammadex available for immediate reversal if needed.

Rocuronium Dosing and Reversal for RSI

1
Step 1 — Calculate the Intubating Dose

The recommended RSI dose of rocuronium is 1.2 mg/kg (approximately 3–4 × the ED₉₅), which provides intubating conditions in 60–90 seconds. For a 70 kg patient: 1.2 mg/kg × 70 kg = 84 mg.

Rocuronium dose = 84 mg IV
2
Step 2 — Predict Onset and Duration

At 1.2 mg/kg, rocuronium achieves intubating conditions in approximately 60 seconds — approaching succinylcholine's onset. However, the higher dose extends the clinical duration to approximately 60–70 minutes (compared to 30–40 minutes at the standard 0.6 mg/kg dose). The team must plan for either a prolonged procedure or have reversal agents prepared.

Onset ≈ 60 sec; Duration ≈ 60–70 min
3
Step 3 — Consider Reversal Strategy

If immediate reversal is needed (e.g., "cannot intubate, cannot oxygenate" scenario), sugammadex at 16 mg/kg can reverse deep rocuronium-induced block within 2–3 minutes. For this 70 kg patient: 16 mg/kg × 70 kg = 1,120 mg sugammadex. This dose is reserved for emergencies. For routine reversal at the end of the case, a lower dose of sugammadex (2–4 mg/kg) or neostigmine (0.04–0.07 mg/kg with glycopyrrolate) may be used once spontaneous recovery has begun (TOF count ≥ 2).

Emergency sugammadex dose = 1,120 mg IV; Routine reversal dose = 140–280 mg IV
4
Step 4 — Verify Adequate Reversal Before Extubation

Regardless of which reversal agent is used, the anesthesiologist must confirm adequate recovery using quantitative neuromuscular monitoring. The standard of care is to demonstrate a train-of-four ratio (TOFR) ≥ 0.9 before extubation. Residual blockade (TOFR < 0.9) is associated with increased risk of postoperative pulmonary complications, aspiration, and hypoxemia.

Target: TOFR ≥ 0.9 before extubation

SECTION 7

Adverse Effects & Drug Interactions

Neuromuscular blockers, while indispensable in perioperative and critical care settings, carry distinct and sometimes life-threatening adverse effect profiles. Understanding these risks is essential for safe prescribing and monitoring. The depolarizing agent succinylcholine has a particularly notable side effect profile that limits its use in many clinical contexts, while non-depolarizing agents vary in their cardiovascular and histamine-releasing properties depending on their chemical class.

Adverse Effect	Succinylcholine (Depolarizing)	Non-Depolarizing Agents
Hyperkalemia	Significant risk (0.5–1.0 mEq/L increase); contraindicated in burns, crush injuries, denervation injuries, prolonged immobilization, and certain myopathies — upregulation of extrajunctional receptors causes massive K⁺ efflux	Not a concern; no depolarization occurs
Malignant Hyperthermia	Known trigger in genetically susceptible individuals (RYR1 mutations); absolute contraindication if family/personal history	Not a trigger; safe in susceptible patients
Bradycardia	Stimulates muscarinic receptors (especially with repeated doses); pretreat with atropine in pediatric patients	Pancuronium causes tachycardia (vagolytic); vecuronium and cisatracurium are cardiovascularly neutral
Histamine Release	Minimal	Atracurium and (to a lesser extent) mivacurium can cause histamine-mediated hypotension, bronchospasm, and flushing; cisatracurium has negligible histamine release
Increased IOP / ICP	Transient increase in intraocular and intragastric pressure due to fasciculations; relative contraindication in open globe injuries	No increase; some agents (e.g., rocuronium) are preferred for open globe procedures
Prolonged Blockade	Occurs in patients with atypical pseudocholinesterase (dibucaine number < 20); can last hours instead of minutes	Accumulation in renal/hepatic failure (pancuronium, vecuronium); drug interactions with aminoglycosides, volatile anesthetics, magnesium

Comparison of adverse effects between depolarizing and non-depolarizing neuromuscular blockers

✦

KEY TAKEAWAY

Think of succinylcholine's side effect profile as the consequence of being "too good" an ACh mimic — it activates everything ACh activates, including muscarinic receptors (bradycardia), nicotinic receptors on all skeletal muscle (fasciculations and potassium release), and intracellular calcium cycling pathways (malignant hyperthermia in susceptible individuals). Non-depolarizing agents, by contrast, are pharmacological "decoys" that occupy but do not activate — they are inert at the receptor, so their side effects arise not from receptor activation but from cross-reactivity with other targets (histamine receptors, muscarinic receptors) or from pharmacokinetic accumulation.

SECTION 8

Neuromuscular Monitoring & Emerging Concepts

Quantitative neuromuscular monitoring has become a cornerstone of safe anesthetic practice. The train-of-four (TOF) stimulation pattern — four supramaximal stimuli delivered at 2 Hz to a peripheral nerve (typically the ulnar nerve at the wrist, monitoring the adductor pollicis) — provides the most clinically useful assessment of the degree and type of neuromuscular blockade. In a non-depolarizing block, fade is observed because the competitive antagonist depletes the presynaptic reserves of ACh with successive stimuli, and fewer receptors remain unblocked for each subsequent response. The TOF ratio (T₄/T₁) quantifies this fade and guides reversal decisions.

Feature	Phase I Block (Depolarizing)	Non-Depolarizing Block
TOF Fade	Absent — all four twitches equally depressed	Present — progressive decrease T₁ > T₂ > T₃ > T₄
Post-Tetanic Potentiation	Absent	Present — increased response after 50 Hz tetanus
Response to Anticholinesterase	Worsened (potentiates depolarizing block)	Reversed (increased ACh competes with blocker)
Effect of Additional NMB	Augmented block	Augmented block (additive for same class; unpredictable for cross-class)
Recovery Pattern	Simultaneous return of all four twitches	Sequential return: T₁ first, then T₂, T₃, T₄

Distinguishing depolarizing (Phase I) and non-depolarizing blocks using peripheral nerve stimulation

Looking ahead, several exciting developments are reshaping the field. Calabadion, a cucurbituril-type molecular container, is being investigated as a universal reversal agent capable of encapsulating both steroidal and benzylisoquinolinium neuromuscular blockers — unlike sugammadex, which is effective only against aminosteroidal agents. Additionally, the development of gantacurium and CW002, ultra-short-acting non-depolarizing agents that undergo rapid cysteine adduction in plasma, may eventually provide an alternative to succinylcholine for RSI without the risk of hyperkalemia or malignant hyperthermia. These advances reflect a broader trend toward designing neuromuscular blockers with built-in degradation mechanisms and universal reversal strategies.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why a non-depolarizing neuromuscular blocker produces fade on train-of-four (TOF) stimulation, whereas succinylcholine (during Phase I block) produces a uniform decrease in all four twitches without fade.

Show answer

Non-depolarizing agents competitively occupy nAChRs. During TOF stimulation at 2 Hz, the motor nerve terminal must mobilize increasingly larger quanta of ACh from reserve pools to sustain transmission across the four stimuli. At a partially blocked NMJ, the first stimulus may generate enough ACh to overcome competitive blockade, but subsequent stimuli progressively fail as presynaptic ACh stores are temporarily depleted and cannot overcome the blocker — producing the characteristic fade pattern (T₄ < T₃ < T₂ < T₁). Succinylcholine in Phase I block, by contrast, maintains the end plate in a depolarized state uniformly; the block does not depend on competitive ACh displacement. Each stimulus finds the same depolarized end plate, so all four twitches are equally depressed. The distinction between fade and no-fade is therefore a direct consequence of the competitive versus depolarizing mechanism of action.

Question 2: BASIC CALCULATION

A 55 kg patient requires intubation using rocuronium at a standard intubating dose of 0.6 mg/kg. Calculate the total dose in milligrams. If the available vial contains rocuronium at a concentration of 10 mg/mL, what volume should be drawn up?

Show answer

The total dose is calculated as 0.6 mg/kg × 55 kg = 33 mg. Given a vial concentration of 10 mg/mL, the volume required is 33 mg ÷ 10 mg/mL = 3.3 mL. This dose will produce intubating conditions in approximately 60–90 seconds with a clinical duration of 30–40 minutes. The anesthesiologist should also prepare a reversal agent, either neostigmine (with glycopyrrolate as an antimuscarinic) or sugammadex, to ensure adequate recovery of neuromuscular function before extubation.

Question 3: INTERMEDIATE

A patient with end-stage renal disease and a creatinine clearance of 8 mL/min requires a non-depolarizing neuromuscular blocker for a 3-hour abdominal surgery. The surgeon requests profound muscle relaxation. Compare the suitability of pancuronium, vecuronium, and cisatracurium for this patient, and justify your recommendation.

Show answer

Pancuronium is the least suitable choice: approximately 70% of its elimination depends on renal excretion, so it would accumulate significantly in this patient, leading to unpredictable prolongation of blockade and difficulty achieving adequate reversal. Vecuronium, while primarily hepatically metabolized, has an active metabolite (3-desacetylvecuronium) that is renally cleared and can accumulate in renal failure, also extending its duration. Cisatracurium is the preferred agent because it undergoes Hofmann elimination — a spontaneous, non-enzymatic degradation at physiological pH and temperature that is completely independent of hepatic and renal function. This organ-independent metabolism makes its pharmacokinetics predictable even in the setting of end-stage renal disease. The anesthesiologist can titrate cisatracurium by infusion or bolus doses with reasonable confidence that recovery will proceed at a normal rate.

Question 4: APPLIED

During a difficult airway scenario, a 90 kg patient received rocuronium 1.2 mg/kg for rapid-sequence intubation. After multiple failed intubation attempts, the team decides to awaken the patient. The anesthesiologist administers sugammadex at the emergency reversal dose of 16 mg/kg. Calculate the sugammadex dose. Explain the molecular mechanism by which sugammadex reverses rocuronium-induced blockade and describe why neostigmine would be a poor choice in this emergency scenario.

Show answer

The sugammadex dose is 16 mg/kg × 90 kg = 1,440 mg, administered as a rapid IV bolus. Sugammadex is a modified γ-cyclodextrin with a hydrophobic central cavity that forms a tight 1:1 inclusion complex with the steroidal rocuronium molecule. By encapsulating free rocuronium in the plasma, sugammadex creates a concentration gradient that draws rocuronium away from the NMJ, effectively terminating blockade within 2–3 minutes even from profound (deep) block. Neostigmine would be a poor choice here for two reasons: first, neostigmine works by inhibiting acetylcholinesterase to increase synaptic ACh, which must then competitively displace rocuronium from the receptor — this mechanism has a ceiling effect and cannot overcome deep block where >95% of receptors are occupied. Second, neostigmine has a slower onset (7–10 minutes) and requires a minimum TOF count of 2 before it can be used effectively. In a life-threatening cannot-intubate-cannot-oxygenate scenario, the delay and unreliability of neostigmine reversal could be fatal.

Question 5: CRITICAL THINKING

A 6-year-old child with an undiagnosed muscular dystrophy (later found to be Duchenne) receives succinylcholine during a routine tonsillectomy and develops acute rhabdomyolysis with a serum potassium of 8.2 mEq/L and cardiac arrest. Analyze the pathophysiology of this event. Why is succinylcholine now subject to an FDA black box warning for pediatric use, and what alternative approach would you recommend for pediatric RSI?

Show answer

In Duchenne muscular dystrophy (and other myopathies), progressive muscle fiber degeneration leads to widespread upregulation of extrajunctional (fetal-type) acetylcholine receptors across the entire muscle fiber membrane, not just the motor end plate. These immature receptors have longer open times and conduct ions less selectively. When succinylcholine depolarizes the entire population of upregulated receptors simultaneously, the resultant potassium efflux is massive — far exceeding the 0.5–1.0 mEq/L rise seen in healthy individuals — producing severe hyperkalemia (>8 mEq/L) that causes ventricular fibrillation or asystole. This sequence — termed hyperkalemic cardiac arrest of anesthesia — has been reported in children with occult myopathies who had no prior diagnosis. Because myopathies may be undiagnosed in young children, the FDA issued a black box warning in 1993 recommending against routine use of succinylcholine in children and adolescents, except in emergency airway situations where no alternative exists. The recommended alternative for pediatric RSI is high-dose rocuronium (1.0–1.2 mg/kg), which achieves intubating conditions in 60–90 seconds and can be rapidly reversed with sugammadex if needed. This approach avoids all depolarization-related complications — hyperkalemia, malignant hyperthermia, myalgias, and increased intracranial/intraocular pressure.

SUMMARY

Neuromuscular Blockers — Summary

Summary

Neuromuscular blockers are pharmacological agents that interrupt transmission at the neuromuscular junction by interfering with nicotinic acetylcholine receptors on the motor end plate. They are divided into two categories: depolarizing agents (succinylcholine), which activate the receptor and then produce sustained depolarization block, and non-depolarizing agents (aminosteroidal and benzylisoquinolinium classes), which competitively prevent ACh from binding without activating the channel. The margin of safety of neuromuscular transmission requires ~75% receptor occupancy before clinical weakness appears and >90% for complete paralysis, explaining the steep dose–response relationship described by the Hill equation with a high Hill coefficient.

Clinically, agent selection depends on the required onset speed, duration of action, patient comorbidities (especially hepatic/renal function), and contraindications. Reversal is achieved through anticholinesterases (neostigmine) or sugammadex (for aminosteroidal agents), and adequate recovery must be confirmed with quantitative neuromuscular monitoring (TOFR ≥ 0.9) before tracheal extubation to prevent residual blockade and postoperative pulmonary complications.